Literature DB >> 19138040

A lower dose threshold for the in vivo protective adaptive response to radiation. Tumorigenesis in chronically exposed normal and Trp53 heterozygous C57BL/6 mice.

R E J Mitchel1, P Burchart, H Wyatt.   

Abstract

Low doses of ionizing radiation to cells and animals may induce adaptive responses that reduce the risk of cancer. However, there are upper dose thresholds above which these protective adaptive responses do not occur. We have now tested the hypothesis that there are similar lower dose thresholds that must be exceeded to induce protective effects in vivo. We examined the effects of low-dose/low-dose-rate fractionated exposures on cancer formation in Trp53 normal or cancer-prone Trp53 heterozygous female C57BL/6 mice. Beginning at 6 weeks of age, mice were exposed 5 days/week to single daily doses (0.33 mGy, 0.7 mGy/h) totaling 48, 97 or 146 mGy over 30, 60 or 90 weeks. The exposures for shorter times (up to 60 weeks) appeared to be below the level necessary to induce overall protective adaptive responses in Trp53 normal mice, and detrimental effects (shortened life span, increased frequency) evident for only specific tumor types (B- and T-cell lymphomas) were produced. Only when the exposures were continued for 90 weeks did the dose become sufficient to induce protective adaptive responses, balancing the detrimental effects for these specific cancers and reducing the risk level back to that of the unexposed animals. Detrimental effects were not seen for other tumor types, and a protective effect was seen for sarcomas after 60 weeks of exposure, which was then lost when the exposure continued for 90 weeks. As shown previously for the upper dose threshold for protection by low doses, the lower dose boundary between protection and harm was influenced by Trp53 functionality. Neither protection nor harm was observed in exposed Trp53 heterozygous mice, indicating that reduced Trp53 function raises the lower dose/ dose-rate threshold for both detrimental and protective tumorigenic effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19138040     DOI: 10.1667/RR1414.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  19 in total

1.  Lung cancer progression using fast switching multiple ion beam radiation and countermeasure prevention.

Authors:  Krishna Luitel; Sang Bum Kim; Summer Barron; James A Richardson; Jerry W Shay
Journal:  Life Sci Space Res (Amst)       Date:  2019-08-01

2.  Radiation induced bystander effects in mice given low doses of radiation in vivo.

Authors:  Harleen Singh; Rohin Saroya; Richard Smith; Rebecca Mantha; Lynda Guindon; Ron E J Mitchel; Colin Seymour; Carmel Mothersill
Journal:  Dose Response       Date:  2010-05-13       Impact factor: 2.658

3.  Human lung cancer risks from radon - part I - influence from bystander effects - a microdose analysis.

Authors:  Bobby E Leonard; Richard E Thompson; Georgia C Beecher
Journal:  Dose Response       Date:  2010-08-20       Impact factor: 2.658

4.  Potential treatment of inflammatory and proliferative diseases by ultra-low doses of ionizing radiations.

Authors:  Charles L Sanders
Journal:  Dose Response       Date:  2012-10-09       Impact factor: 2.658

5.  Low-dose cancer risk modeling must recognize up-regulation of protection.

Authors:  Ludwig E Feinendegen; Myron Pollycove; Ronald D Neumann
Journal:  Dose Response       Date:  2009-12-10       Impact factor: 2.658

6.  The dose window for radiation-induced protective adaptive responses.

Authors:  Ronald E J Mitchel
Journal:  Dose Response       Date:  2009-11-23       Impact factor: 2.658

7.  Immunological mechanism of low-dose priming radiation resistance in walker-256 tumor model mice.

Authors:  Li Feng; Ling Qin; Dan Guo; Daping Deng; Feng Lu; Hailiang Li; Narisu Bao; Xiting Yang; Hongyu Ding; Jianguo Li
Journal:  Exp Ther Med       Date:  2017-08-21       Impact factor: 2.447

8.  Human Lung Cancer Risks from Radon - Part II - Influence from Combined Adaptive Response and Bystander Effects - A Microdose Analysis.

Authors:  Bobby E Leonard; Richard E Thompson; Georgia C Beecher
Journal:  Dose Response       Date:  2010-01-19       Impact factor: 2.658

Review 9.  New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents.

Authors:  Katerina Gurova
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

10.  Radioiodine remnant ablation of differentiated thyroid cancer does not further increase oxidative damage to membrane lipids - early effect.

Authors:  Jacek Makarewicz; Andrzej Lewiński; Małgorzata Karbownik-Lewińska
Journal:  Thyroid Res       Date:  2010-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.